<DOC>
	<DOC>NCT00595140</DOC>
	<brief_summary>The purpose of the study is to investigate the efficacy of an acute additional application of the somatostatin analogue octreotide 100Âµg s.c. or the dopamine agonist cabergoline 0.5mg p.o. to the receptor antagonist pegvisomant during a 6 or 9 hour profile on reducing endogenous growth hormone in patients with acromegaly on stable pegvisomant therapy.</brief_summary>
	<brief_title>Acute Application of Pegvisomant and Octreotide in Acromegaly</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Cabergoline</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<mesh_term>Dopamine Agonists</mesh_term>
	<criteria>patients with acromegaly currently on stable pegvisomant therapy patients with diabetes mellitus may be included. Glucose levels must be controlled regularly throughout the study patients must not be cotreated with any other medication for acromegaly radiotherapy within the last 2 years any relevant acute disease history of hypersensitivity against any of the used drugs pregnancy or lactation abnormal baseline findings</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Acromegaly,</keyword>
	<keyword>growth hormone receptor antagonist,</keyword>
	<keyword>somatostatin analogue,</keyword>
	<keyword>combined medical treatment,</keyword>
	<keyword>acute effect,</keyword>
	<keyword>endogenous GH</keyword>
</DOC>